Clinical trials: Fibrotic Interstitial Lungs Diseases
Idiopathic Pulmonary Fibrosis, Cough
Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)
Orally administered ME-015 (Suplatast Tosilate) has been available on the market as a prescription drug for allergy-related conditions in Japan since 1995 with a good safety and tolerability profile.
- Conditions
- Idiopathic Pulmonary Fibrosis, Cough, IPF, Fibrotic Lung Disease
- Trial name
- COSMIC-IPF (NCT05983471)
- Testing
- ME-015 (Suplatast Tosilate)
- Where
- 6 sites in India
- Volunteers
- 40 people
- Sponsor
- Melius Pharma AB
Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease
Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia
Fibrotic forms of interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are chronic lung disease which often affect how well oxygen can get from the lungs into the blood.
- Conditions
- Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Hypoxemia
- Trial name
- NCT07512687
- Testing
- Portable Oxygen Concentrator, Portable compressed oxygen D-tanks, No ambulatory oxygen therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- State University of New York at Buffalo
Fibrotic Interstitial Lung Disease
Mechanistic 129 Xe MRI Study to Assess Therapeutic Response in Fibrotic Interstitial Lung Disease
The goal of this observational study is to better understand how treatment affects the lungs of adults (ages 18-80) with fibrotic interstitial lung diseases.
- Trial name
- MASTER-ILD (NCT07786090)
- Testing
- Hyperpolarized 129Xe MRI
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Dr. Grace Parraga
Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.
- Conditions
- Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary, Dermatomyositis, Rheumatoid Arthritis
- Trial name
- RMD-mILDer (NCT06732674)
- Testing
- A home monitoring strategy with event driven management
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- Oslo University Hospital
Interstitial Lung Disease (ILD)
Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China
This project aimed to: 1) construct a cohort of no less than 10000 cases of f-ILD (including pneumoconiosis ≥3000 cases) with continuous regular follow-up to reveal the clinical phenotypes closely related to the development…
- Trial name
- NCT06655090
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Dai Huaping
Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound
- Trial name
- AF-BMC (NCT07332117)
- Testing
- No Interventions, No intervention
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF)
Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive scarring of lung tissue, leading to declining lung…
- Conditions
- Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Trial name
- NCT07466420
- Testing
- Quercetin (dietary supplement), Usual treatment
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Katerina M. Antoniou
Interstitial Lung Disease, Fibrosis Lung
FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion
This is an observational clinical research study investigating patients with fibrotic interstitial lung disease (fILD), also known as pulmonary fibrosis. It is not known why some patients with fILD clinically deteriorate.
- Conditions
- Interstitial Lung Disease, Fibrosis Lung, Pulmonary Hypertension
- Trial name
- FIBRINOX-EXTRA (NCT06416163)
- Testing
- Prospective
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Fibrosis Lung, Respiratory Therapy
Automated Oxygen Titration During Walking in Patients With Lung Fibrosis (OXYWILD)
Fibrotic lung disease is a group of severe scarring lung diseases with a dismal prognosis, often leading to respiratory failure and need for oxygen treatment.
- Trial name
- OXYWILD (NCT06465654)
- Testing
- Automated variable dose oxygen treatment, Fixed dose oxygen treatment
- Where
- Denmark
- Volunteers
- 29 people
- Sponsor
- Janne Hastrup Jensen
Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
This study will investigate whether the senicapoc drug can prevent the scarring from worsening in interstitial lung disease. Researchers will compare Senicapoc to a placebo (a look-alike substance that contains no drug) to see if…
- Trial name
- FIBROPOC (NCT06714123)
- Testing
- Senicapoc
- Where
- 5 sites in Denmark, Estonia and 1 more
- Volunteers
- 140 people
- Sponsor
- Vejle Hospital
Interstitial Lung Disease, Fibrotic Lung Disease
Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease
Patients with fibrotic insterstitial lung disease (ILD) participating in inpatient rehabilitation or in outpatient pulmonary care will be invited to participate in this observational study.
- Conditions
- Interstitial Lung Disease, Fibrotic Lung Disease, Self Efficacy, Self-management
- Trial name
- NCT06027333
- Testing
- Inpatient rehabilitation (BRZ) or regular outpatient consultations (Insel), Blended patient education and self-management programme (PESM)
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people
- Sponsor
- Berner Reha Zentrum AG
Pulmonary Fibrosis, Pulmonary Hypertension
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension
A randomized, double-blind, placebo-controlled dose escalation and verification study to assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for pulmonary hypertension associated with pulmonary…
- Trial name
- REBUILD (NCT03267108)
- Testing
- INOpulse®, Open Label Extension
- Where
- 64 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- Bellerophon Pulse Technologies
Interstitial Lung Disease (ILD)
Nasal High-flow Oxygen Therapy During Rehabilitive Exercise Training in ILD
Although uncommon, interstitial lung diseases (ILDs), and particularly idiopathic pulmonary fibrosis (IPF), are progressive, irreversible, and ultimately fatal without treatment.
- Trial name
- PID-OX (NCT07679854)
- Testing
- Pulmonary rehabilitation with NHFO2, Pulmonary rehabiltation with conventional oxygen therapy
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Frédéric Hérengt
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Toward Self-management in ILD
Treating and caring for people with long term conditions accounts for a substantial proportion of health care resources. Self-management is advocated as a mechanism that can empower service users with long term conditions to…
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Connective Tissue Related ILD, Chronic Hypersensitivity Pneumonitis
- Trial name
- NCT03300583
- Testing
- Focus groups, Semi-structured interviews
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Kingston University
Fibrotic Interstitial Lung Disease
Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease
Our study aims to investigate the benefits of an outpatient pulmonary rehabilitation program in a population of subjects with fibrotic interstitial lung disease.
- Trial name
- NCT00415272
- Testing
- Pulmonary Rehabilitation
- Where
- United States
- Sponsor
- University of California, San Francisco
Idiopathic Pulmonary Fibrosis
Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Life
In this study it will be investigate whether a home monitoring program improves disease-specific health-related quality of life (HRQOL) for patients with idiopathic pulmonary fibrosis (IPF) through appropriate medication use and…
- Trial name
- NCT03420235
- Testing
- Home monitoring program
- Where
- Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Idiopathic Pulmonary Fibrosis
This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.
The primary objective is to investigate safety and tolerability of BI 1015550 in patients with IPF. The secondary objectives are to evaluate the pharmacokinetics (PK) of BI 1015550 in patients with IPF.
- Trial name
- NCT03422068
- Testing
- BI 1015550
- Where
- 11 sites in Denmark, Finland and 5 more
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to…
- Conditions
- Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury
- Trial name
- NCT07613099
- Testing
- [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
- Conditions
- Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
- Trial name
- TETON-OLE (NCT04905693)
- Testing
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Where
- 192 sites in United States, Argentina and 16 more
- Volunteers
- 1,850 people
- Sponsor
- United Therapeutics
Stage 4 Pulmonary Sarcoidosis
Pulmonary Rehabilitation in Patients With Sarcoidosis
The primary objective of the study is to assess the improvement of daily activity in subjects with Stage IV Pulmonary Sarcoidosis one year after the conduct of a pulmonary rehabilitation program.
- Trial name
- NCT02044939
- Testing
- Pulmonary rehabilitation program
- Where
- 11 sites in France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Lille